Dr. med. Laure Thouvenin

• European Society for Medical Oncology (ESMO)
• Association Suisse des Médecins (FMH) (en cours)
• Association des Médecins du canton de Genève (AMGe) (en cours)
• Société Suisse d’Oncologie Médicale (SSOM) (en cours)

Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland. S Colomer-Lahiguera, C Canella, S Giacomini, K Lê Van, C Pedrazzani, M Naegele, L Thouvenin, A O'Meara Stern, R Condorelli, T Corbière, C Witt, M Eicher, K Ribi. Support Care Cancer. 2023 Jun 22;31(7):410. doi: 10.1007/s00520-023-07871-8.

Differential impact of tamoxifen and aromatase inhibitors on thrombin generation : the prospective HEMOBREAST cohort. Blondon M, Bodmer A, Thouvenin L, Lecompte T, Righini M, Fontana P, Casini A.Blood Adv. 2022 May 10;6(9):2884-2892. doi: 10.1182/bloodadvances.2021006623

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab. Thouvenin L, Charrier M, Clement S, Christinat Y, Tille JC, Frigeri M, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P.Gynecol Oncol Rep. 2021 May 19;37:100787. doi: 10.1016/j.gore.2021.100787. eCollection 2021 Aug

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis : a case-series and narrative review. Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A. Ther Adv Drug Saf. 2021 Mar 29;12:20420986211004745. doi: 10.1177/20420986211004745. eCollection 2021

A new hope in the treatment of hepatocellular carcinoma. Thouvenin L, Friedlaender A.Rev Med Suisse. 2020 May 27;16(695):1074-1078

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss. Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P.Cancer Biol Ther. 2020;21(3):197-202. doi: 10.1080/15384047.2019.1685291. Epub 2019 Nov 10

Monoclonal gammopathies: from MGUS to multiple myeloma. Thouvenin L, Lang N.Rev Med Suisse. 2019 May 15;15(651):1022-1026